Acute phase proteins are released from the liver in response to cytokines, and
Multiple nucleated cells including macrophages and circulating blood monocytes are capable of producing cytokine mediators such as interleukin-113) (IL-113), tumour necrosis factor (TNF-a), and interleukin-6 (IL-6).' Attention has now turned to these as potential mediators of inflammation in inflammatory bowel disease. Cytokines may play this part in the mucosa, and in addition be responsible for some systemic reactions in inflammatory bowel disease. Many clinical and biochemical features of ulcerative colitis and Crohn's disease including fever, increased production of acute phase reactants, hypoalbuminaemia, and fibroblast proliferation with fibrosis may be attributable to the actions of cytokines. 2 Activated macrophages and monocytes produce a panel of cytokines with different but sometimes overlapping actions. IL-13 and TNFa are notably proinflammatory, being important early signals in the inflammatory process that can induce regulatory changes in a wide variety of cell types, as well as initiating the release of a cascade of other mediators.34 IL-1,B and TNF-a can also stimulate each others' production in vitro and in vivo.' There are differences in the spectrum of actions of IL-6,6 which can be induced by IL-I and TNF-a, does not stimulate IL-1 or TNF production, and indeed has been shown to inhibit their synthesis by macrophages in vitro, implying that at least some of its actions down regulate the amplificatory actions of cytokines.67 A growing body of evidence, referred to later, points to an enhanced production of many cytokines in inflammatory bowel disease.
Our interest in the role of cytokines developed from two related aspects of inflammatory bowel disease. The uncertain relation between ulcerative colitis and Crohn's disease -whether different conditions or part of a continuous disease spectrum -prompts careful examination of those differences that can be defined. The interest in our laboratory on the assessment of the inflammatory activity of these conditions, particularly the use of acute phase reactants, highlighted one such difference, the tendency to find greater increases in circulating C-reactive protein (CRP) in patients with active Crohn's disease compared with ulcerative colitis.89 CRP is generated by the liver in response to cytokines, and both IL-13 and IL-6 enhance CRP production, the first at a translational and the second at a transcriptional level.'"0' We reported that -for each monocyte -cells from Crohn's disease patients produce more IL-113 than cells from ulcerative colitis patients or controls, compatible with the suggestion that there is an innate difference between the tendency for patients with Crohn's disease and ulcerative colitis to produce this cytokine when stimulated. 12 Patients with Crohn's disease were also recently reported to have increased plasma concentrations compared with ulcerative colitis.' '6 The first aim of this study was therefore to confirm whether production of IL-6 by peripheral blood monocytes, as representatives of the monocyte macrophage lineage, was increased in Crohn's disease compared with ulcerative colitis, again exploring whether there were qualitative rather than merely quantitative differences behind the differences in acute phase response in these two conditions. We therefore measured IL-6 production in patients with Crohn's disease and ulcerative colitis. We assessed in vitro release of cytokine from monocytes after stimulation with lipopolysaccharide, and used a fixed number of cells, to avoid the possibility that a greater cytokine response in Crohn's disease might merely reflect a greater number of cells participating in the inflammatory response. We also measured IL-1,B in this second series of patients.
The second aim of this study was to see if differences in the profile of cytokines present in Crohn's disease and ulcerative colitis could account for the greater CRP response associated with active Crohn's disease. We therefore assessed the effect of the cytokine rich monocyte conditioned media, of known IL-13 and IL-6 concentration, in initiating release ofCRP from a hepatocyte derived cell line, to find out if the CRP response could be attributed to one or other cytokine predominantly. We assessed the value of this in vitro model, by checking if the CRP released in vitro correlated with the circulating CRP concentrations in the patients from whom the monocytes had been harvested.
Patients and methods

PATIENTS AND CONTROLS
Patients with inflammatory bowel disease included in this study consisted of 22 patients with Crohn's disease (11 males and 11 females; age: mean (range) 37-9 (23-62) y) and 22 patients with ulcerative colitis (12 males and 10 females; age 45-0 (19-79) y). Eleven healthy volunteers comprising of six men and five women (age 39 9 (30-62) y) served as normal controls.
DISEASE ACTIVITY
In the Crohn's disease group 11 patients were quiescent (Harvey-Bradshaw index of 1) and 11 had active disease (Harvey-Bradshaw index: mean (SEM) 6 2 (0 8)). '7 In terms ofextent of the disease, nine patients had ileitis, five ileocolitis, and eight colitis. Eleven patients with ulcerative colitis were active (Truelove and Witts),'8 seven mildly and four moderately. In terms of disease distribution, one patient had pancolitis, 17 had left colon involvement (four proctosigmoiditis, nine had involvement of the rectum, sigmoid, and descending colon, and four had involvement ofthe rectum, descending, and transverse colon), and four had disease limited to the rectum. TREATMENT 
GROUPS
In the Crohn's disease group eight patients were not receiving treatment. Four patients were receiving sulphasalazine; one of these was also receiving prednisolone. Three patients were being treated with 5-aminosalicylic acid (5-ASA); two of these were also receiving prednisolone. 12 The lower detection limit of the CRP assay was 0 05 ng/ml, with a 7% coefficient of variation in assay and 15% between assay.
ELISA FOR IL-1 3 Quantitative estimation of IL-13 was performed in duplicate. High binding ELISA plates (Greiner, UK: 655061) were coated with 100 dl/well, rabbit-recombinant human IL-13 (Universal Biologicals, UK) at a concentration of 5 ,ul in coating buffer (0 05 M carbonate; pH 9 6) for at least three days (88 hours) at 4°C. After washing three times with phosphate buffered saline containing 0-05% TWEEN-20 (PBS/ 0-05% Tween-20; wash buffer) plates were blocked with blocking buffer (PBS with 1% BSA; 100 ml/well) for four hours at room temperature. After three washes 100 ml of supernatant medium samples containing IL-113 or recombinant human IL-13 standards (British Bio-technology, UK) in doubling dilutions (20 pg/ml-100 ng/ml; standards diluted in complete medium), were added and the plates incubated overnight (16 hours) at 37°C in a moist box. After four washes 100 il/goat anti-human IL-1l6 (British Bio-technology, UK) at a concentration of 1 mg/ml (diluted in. conjugate buffer; PBS/ 0-5% BSA) were added and the plates incubated for two hours at 37°C. After four washes, 100 ml/well peroxidase conjugated affinipure donkey anti-goat IgG (Jackson Immunoresearch Laboratories, USA) diluted 1:2000 in conjugate buffer (PBS/0*5% BSA) was added and the plates incubated at room temperature for a further two hours. After five washes substrate solution (H202-OPD; 100 ml/well) was added and the plates were incubated in the dark at room temperature. The reaction was terminated by adding 100 ,u13M sulphuric acid and absorbance read at 492 nm in an ELISA plate reader. The lower detection limit was 20 pg/ml, with a 7 1% within and 5-4% between assay coefficient of variation.
ELISA FOR IL-6 IL-6 estimation was performed in duplicate. High binding ELISA microtitre plates (Greiner, UK; 655061) were coated with 100 Fii/well rabbit anti-recombinant human IL-6 (genzyme) at a concentration of 5 mg/ml in coating buffer (0-05 M carbonate; pH 9 6) for at least two days (64 hours) at 4°C. After washing three times with phosphate buffered saline containing 0-05% TWEEN-20 (PBS/0-05% Tween-20; wash buffer) plates were blocked with blocking buffer (PBS with 1% BSA; 100 ml/well) for two hours at room temperature. Plates were then washed again three times before adding 100 ,tl of supernatant medium samples containing IL-6 or IL-6 standards in doubling dilutions (50 pg/ ml-50 ng/ml; standards diluted in complete medium). The plates were then incubated for two hours at 37°C in a moist box. The number of peripheral blood monocytes for Crohn's disease (mean (SEM) 5-3 (0-4)x 105/ml) was greater compared with ulcerative colitis (4-6 (0-35)x 105/ml; p>005) and normal controls (3-3 (0 25)x105/ml; p<005), although the difference was only significant when compared with normal controls. Among the patients with inflammatory bowel disease, those who had active inflammation (mean (SEM) 5-4 (0*4)x 105/ ml; p<005) had significantly greater monocyte counts than those without (4-6 (0-35)x 10'/ml) similar to the findings described above.
IN VITRO PRODUCTION OF IL-113 RELATED TO TOTAL MONOCYTE COUNT Calculated spontaneous and lipopolysaccharide stimulated production of IL-1,B, related to total count of monocytes per 10 ml blood, were both strikingly and statistically significantly raised in Crohn's disease compared with ulcerative colitis and normal controls (Table) .
Both spontaneous and lipopolysaccharide stimulated IL-1l6 release related to total monocyte count per 10 ml blood from patients with inactive Crohn's disease were significantly raised compared with inactive ulcerative colitis. In active Crohn's disease lipopolysaccharide stimulated IL-1lB production related to total count of monocytes per 10 ml of patients blood was raised compared with active ulcerative colitis. There was no statistical difference In vitro interleukin-l1i (IL--), and interleukin-6 (IL-6) production related to total monocyte count per 10 ml blood obtainedfrom patients with ulcerative colitis, Crohn's disease, and Calculated spontaneous and lipopolysaccharide stimulated IL-6 production related to the total count of monocytes per 10 ml blood from patients with Crohn's disease were both significantly greater than from patients with ulcerative colitis (Table) . In normal controls both spontaneous and lipopolysaccharide stimulated IL-6 release related to total monocyte count were similar to ulcerative colitis. Lipopolysaccharide stimulated IL-6 generation from controls was less than from patients with Crohn's disease (p<005), but spontaneous IL-6 generation did not differ significantly between these two groups. When and normal controls (p<0-002), as well as inactive Crohn's disease (p<0-005) (Fig 2) .
CORRELATION OF SERUM CRP WITH IN VITRO CRP RELEASE
In inflammatory bowel disease patients we found a significant correlation between serum CRP, and in vitro CRP release in response to monocyte conditioned medium in the absence of lipopolysaccharide (r=0-28; p<0005) but not in the presence of lipopolysaccharide (r=0-17; p>0.05).
Discussion
In this study we investigated differences in the following parameters between ulcerative colitis and Crohn's disease: (a) serum CRP concentrations, (b) release of the cytokines IL-6 and IL-1I from monocytes, and (c) the effects of these monocyte conditioned media on an in vitro model of CRP release. trols (0-61 (0-09) ng/ml and [-30 (0-12) nglml respectively) (Fig 1) .
Both unstimulated and lipopolysaccharide stimulated monocyte conditioned medium from patients with active Crohn's disease (mean (SEM) [-73 (0-40) ng/ml and 3-48 (0-87) ng/ml respectively) caused significantly greater CRP release from Alexander cells than monocyte conditioned medium from active ulcerative colitis (0-67 (0d17) ng/ml; p<0-02 and 2-01 (0-38) ng/ml; p<0-05 respectively) and normal controls (0-61 (0-09) ng/ml; .p<0-02 and [-30 (0-12) ng/ml; p<0-002 respectively) (Fig 1) . There is emerging evidence from a number of studies of differences in the tendency of patients with Crohn's disease and ulcerative colitis to produce cytokines IL-1l8 and IL-6. Raised serum concentrations of IL-1B have been reported in patients with acute exacerbations of Crohn's disease, but not those with quiescent disease.'42423 In patients with ulcerative colitis IL-1,13 activity was rarely found in the plasma even during active disease.26 Several groups report that circulating IL-6 concentrations are higher in Crohn's disease compared with ulcerative colitis.'31-6 We have investigated one source of these cytokines, the monocytes from peripheral blood as a representative of the monocytemacrophage series, and have attempted to discover if there are differences in IL-,13 and IL-6 production between the two diseases.
In this second study, in a new series of patients, we confirmed our previous report that interleukin-l,B production by peripheral blood monocytes is greater in Crohn's disease than ulcerative colitis.'2 We showed this with a fixed number of monocytes from each patient, so the difference in IL-1B production between the two conditions was not due to the trivial explanation that a greater number of monocytes were studied in the cell population sampled in Crohn's disease. The results suggest a genuine difference in the capacity of Crohn's disease monocytes to produce IL-1P. In addition, however, the greater number of circulating monocytes implies that in Crohn's disease IL-i1 expression may be even greater, and at the tissue level macrophages are particularly prominent in Crohn's disease. Thus, a higher IL-i,B circulating concentration in Crohn's disease compared with ulcerative colitis probably reflects both a greater potential for cells of the monocyte-macrophage series to generate this cytokine and also a greater number of cells affected.
In contrast with the above findings we found that IL-6 production by a given number of 
